
Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses the need for increased pharmacy benefit manager regulation on a federal level.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses the need for increased pharmacy benefit manager regulation on a federal level.

Robert F. Sidonio Jr, MD, assistant professor of pediatrics at Emory University, Children's Healthcare of Atlanta, discusses how a multi-disciplinary clinic model improves patient care in hemophilia treatment centers.

In this clip, Lee Golden, PharmD from TwelveStone Health shares how his pharmacy is working toward innovative, high quality care with their new infusion center.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses the key role of specialty pharmacy in supporting patients and the health care team.

Robert F. Sidonio Jr, MD, assistant professor of pediatrics at Emory University, Children's Healthcare of Atlanta, gives an overview of the different hemophilia therapies and recent improvements in the treatment landscape.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, gives an overview of the exciting therapeutic developments in the B-cell lymphoma space.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, talks about how technology can enhance patient care from a pharmacy perspective.

Doris Quon, MD, Medical Director at the Orthopaedic Hemophilia Treatment Center, discusses the main takeaways from phase 3 HAVEN trial data for emicizumab (Hemlibra) prophylaxis in hemophilia.

Pharmacy Times’ Ed Cohen, PharmD, FAPha, interviews Miranda Rochol, Healthcare Product Management & Strategy Executive for IQVIA, about opportunities for pharmacy professionals utilizing the company’s services.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, talks about how different providers must work together to ensure the success of a value-based care system.

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, discusses the collaborative approach taken at his clinic in the management and treatment of patients with hemophilia.

Ed Cohen discusses platform integration in the pharmacy.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the increasing cost burden of cancer therapies and future strategies for mitigating costs.

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, talks about new therapies for hemophilia and exciting advancements on the horizon.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses specialty areas experiencing innovative developments in therapies.

Thom Cohn, Chief Strategy Officer, Asembia, discusses special considerations for the launch of a personalized drug.

In this clip, Pharmacy Times' Ed Cohen interviews' IQVIA representative Miranda Rochol about the company's services for pharmacists.

Robert F. Sidonio Jr, MD, assistant professor of pediatrics at Emory University, Children's Healthcare of Atlanta, gives an overview of the challenges associated with hemophilia management.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, provides insight into the future of Any Willing Provider laws for the pharmacy industry.

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, discusses how pharmacokinetics has helped patients with hemophilia better manage their disease.

Mike Agostino, RPh, President of the National Association of Specialty Pharmacy (NASP), discusses the specialty pharmacist's role in taking a value-based approach to patient care.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses how specialty pharmacies can use technology to enhance patient care.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses how the growing number of PBM-owned specialty pharmacies could impact the pharmacy industry.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses the key components of the American Patients First drug pricing blueprint and how the plan could affect specialty pharmacy.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses how collaboration with manufacturers can help specialty pharmacies prepare from a patient services and distribution perspective.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses the challenges that consolidation brings to the pharmacy industry and how specialty pharmacies can face those challenges.

Mike Agostino, RPh, President of the National Association of Specialty Pharmacy (NASP), discusses how NASP has grown to meet the evolving needs of the pharmacy profession.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the emergence of CAR T-cell therapy as a groundbreaking oncology treatment.

At the 2018 National Association of Specialty Pharmacy (NASP) Annual Meeting and Educational Conference, Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discussed several pieces of legislation in Congress that could impact specialty pharmacy.

At the 2018 National Association of Specialty Pharmacy (NASP) Annual Meeting and Educational Conference, Mike Agostino, RPh, President of NASP, discussed how the organization advocates for the profession.